Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
Kevin L WinthropGustavo CiteraDavid GoldDan HenrohnCarol A ConnellAndrea B ShapiroHarry ShiAlina M OnofreiDimitrios A PappasHendrik Schulze-KoopsPublished in: Annals of the rheumatic diseases (2020)